Navigation Links
Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor
Date:4/8/2013

SUNNYVALE, Calif., April 8, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.

This study was discussed at today's American Association for Cancer Research (AACR) annual meeting in Washington, DC together in addition to 8 other presentations covering advances in clinical and pre-clinical research with ibrutinib. The Phase II study, which was sponsored by the National Heart, Lung and Blood Institute, included an analysis of two CLL patient cohorts: the elderly, above 65 years of age, (n=24, of which 8 were treatment naive) and the high risk genetic group with a deletion of chromosome 17p (del 17p) (n=29, of which 15 were treatment naive). Many elderly patients with CLL are unable to tolerate aggressive therapies. Patients with deletion of chromosome 17p typically are poor responders to chemoimmunotherapy and have limited treatment options with no standard of care defined. Of all CLL patients enrolled in this trial, 72% had been characterized as Rai stage 3-4, indicating an advance stage, high risk patient population.

The results of the study were presented by lead investigator Adrian Wiestner , M.D., PhD, Hematology Branch, NHLBI, National Institutes of Health. "Ibrutinib was highly efficacious as a single agent in patients with untreated, relapsed and unresponsive CLL, irrespective of their del 17p status," Dr. Wiestner said. "Responses in this study appear to be durable, and results indicate the drug is effective against the disease in lymph nodes, spleen and
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Zafgen, Inc., a leading biopharmaceutical ... severely obese patients, today announced initial results from ... inhibitor of methionine aminopeptidase 2 (MetAP2), in patients ... genetic obesity.  These results showed improvements in body ...
(Date:1/14/2014)... 2014 InformEx, North America,s leading ... will hold the 30 th edition of its annual ... Center from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... fine chemical and specialty chemical companies will take part in ...
(Date:1/14/2014)... LEESBURG, Va. , Jan. 14, 2014 Animal Emergency Critical ... in Leesburg, Virginia is the first in ... hyperbaric oxygen chamber. Dr. Susan M. Barnes ... years. Dr. Barnes and husband, Dr. Cole Taylor , are ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
... PRO-DEX, INC. (Nasdaq: PDEX ) invites investors and ... fiscal 2011 fourth quarter and full-year financial results. ... the internet on Wednesday, September 14, 2011 at 4:30 p.m. ... by visiting the Company,s website at www.pro-dex.com and ...
... (NASDAQ: PCYC ), a biopharmaceutical company focused ... the treatment of cancer and immune mediated diseases, today ... fourth fiscal quarter and fiscal year ended June 30, ... 12, 2011.  The company will conduct a conference call ...
Cached Medicine Technology:Pro-Dex, Inc. Announces Fiscal 2011 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast 2Pharmacyclics Announces Date of Fiscal Year End 2011 Financial Results and Conference Call 2
(Date:4/20/2014)... harmful effects in children, codeine continues to be prescribed ... UCSF Benioff Children,s Hospital San Francisco. , As reported ... include changing provider prescription behaviors to promote the use ... hydrocodone. , "Despite strong evidence against the use of ... to large numbers of them each year," said Sunitha ...
(Date:4/18/2014)... in The Gerontologist reports that ... with a decrease in anxiety about death and increases ... their lives. In particular, listening to gospel music is ... an increase in sense of control. , These associations ... and individuals of both low- and high-socioeconomic status. , ...
(Date:4/18/2014)... a brain-related discovery that could revolutionize doctors, perception ... opens up the possibility that environmental and/or genetic ... activity that the researchers have identified as helping ... Neuroscience has just published a paper about ... of psychology and his doctoral student John Gaspar, ...
(Date:4/17/2014)... chronic inflammation in non-cancerous prostate tissue may have nearly ... those with no inflammation, according to results of a ... Kimmel Cancer Center. , The link between persistent inflammation ... high-grade prostate cancer those with a Gleason score ... the most aggressive and rapidly growing prostate cancers. , ...
(Date:4/17/2014)... Experimental Biology and Medicine a multidisciplinary research ... Kenis in the Institute of Genomic Biology (IGB) ... Urbana-Champaign describe their recent work on subcellular redox ... cell functions including energy metabolism, signaling, and transcriptional ... normal cellular behavior, redox status has been recognized ...
Breaking Medicine News(10 mins):Health News:UCSF study finds codeine often prescribed to children, despite available alternatives 2Health News:Religious music brings benefit to seniors' mental health 2Health News:Scientists discover brain's anti-distraction system 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2
... , , , MANHATTAN, Kan., ... work of a K-State researcher are making headway in the effort ... Juergen Richt is a Regents Distinguished Professor at K-State,s College of ... work at K-State and with outside collaborators is revealing the characteristics ...
... Experts urge parents to get their kids, eyes checked regularly ... percent of kids aged 12 to 17 have trouble seeing ... the nearly 1,500 children in the survey, more than 25 ... though 45 percent of them wore some type of prescription ...
... , CHESTNUT HILL, Mass., Aug. 3 SkinCare ... live Artefill patient demonstration at the American Academy of Dermatology Summer ... collagen filler for the correction of smile lines and was one ... 31st. , , "Over the past several years ...
... , ALLEGAN, Mich., Aug. 3 Perrigo Company (Nasdaq: ... Pharmaceutical Industries Ltd. (Nasdaq: TEVA ) (previously Barr Laboratories ... Administration to market Triamcinolone Acetonide Nasal Spray containing a paragraph IV ... complete ANDA with a Paragraph IV certification for NASACORT AQ. The ...
... equipment alone is responsible for an increased number of ... to a study performed at San Luis Diagnostic Center ... that there was a significant increase in the number ... to digital mammography. The number of cancers detected prior ...
... in French . Heavy drinkers of ... cancer than the population at large, says a group of ... in the highest consumption category increased their risk of developing ... cancer by 50%. In all, the researchers found ...
Cached Medicine News:Health News:K-State Researcher, Collaborators Study Virulence of Pandemic H1N1 Virus; Work at K-State Would Protect Pig Industry If the Virus Jumps to Swine Populations 2Health News:Leading Boston Dermatologist Performs Live Artefill Patient Demonstration at American Academy of Dermatology Summer Meeting 2Health News:Perrigo Announces FDA Approval for Generic Version of NASACORT(R) AQ 2Health News:Perrigo Announces FDA Approval for Generic Version of NASACORT(R) AQ 3Health News:Heavy drinkers face significantly increased cancer risk 2
... Lomb PMMA Anterior Chamber Intraocular Lenses are ... in patients 60 years of age or ... removed by primary intracapsular cataract extraction; or ... a structural reason that the anterior chamber ...
... Amvisc Plus is the preferred viscoelastic ... viscoelastic that reliably works from the start ... unique, moderately cohesive profile of this viscoelastic ... vacuum forces associated with phacoemulsification remove only ...
... ENDOGEL is a sterile, non-pyrogenic solution ... is supplied in a disposable single ... fitting, delivering 0,85 ml. Sodium ... of repetitive chains of disaccharides, glucoronate, ...
... a sterile, non-pyrogenic, transparent viscoelastic preparation ... molecular weight (average molecular weight 4 ... 23 mg/mL of sodium hyaluronate 5000, ... N-acetylglucosamine and sodium glucuronate linked by ...
Medicine Products: